🔗 Share this article

Given that the US undertakes sweeping adjustments to its vaccine recommendations, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by questioning coronavirus vaccines in the pandemic and has concentrated on potential fatalities after COVID-19 immunization in her recent tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Schedule

Health officials had intended to announce sweeping changes to the childhood immunization program recently, synchronizing the US with the Danish immunization schedule, sources say – a major change that would place the US out of step with many the international standard with no evidence for benefit. This reveal has been postponed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s CDER, the fifth individual to run the center this calendar year.

A New Direction at the FDA

This interim role may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon rolling back long-standing vaccines at the FDA.

Høeg has often pushed for discontinuing some childhood vaccine recommendations in the US so as to align more in line with the Danish model, a society with comprehensive healthcare and a population about the population of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, chief of the FDA’s CBER – instead of medication approval.

Concerns Over Expertise

Høeg has no obvious experience in drug development, oversight or administrative roles, which has been customary for past directors of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former heads of the center would “be deeply familiar with legal statutes and the science of drug development”, noted Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who led CBER have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the novel medication approvals, but the generic drug division authorizes numerous off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and so forth, and each of these need to be managed,” she said. “The thing you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership aspect to the position, which manages more than 5,000 staff members. “It’s a enormous administrative position, if you perform it correctly,” she added.

Agency Reaction and Controversial Programs

In response to questions about Dr. Høeg's credentials and whether this appointment indicates more teamwork among agency officials on immunizations, a representative responded that the “concerns stem from inaccurate presumptions”.

“Her experience is consistent with the duties of her role,” the spokesperson said, citing the months Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s controversial expedited review system, a contentious one-day therapy clearance system that allegedly worried her former heads. “How are these therapies being chosen for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he stated, “the FDA looks to be trending towards laxer rules of all drugs, with the exception of shots.”

Established Past Work on Vaccines

With immunizations, Høeg has a more documented, if problematic, track record, Howard observe. She authored a study using unconfirmed volunteer-provided data to estimate the rate of heart inflammation after COVID-19 immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “wish list” for the new government included changing guidelines for new vaccines and halting “unnecessary” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has reportedly suggested excluding adolescent males from getting Covid vaccines.

“She’s an all-around true believer who begins with her beliefs and reverse-engineers to retrofit the science in a very deceptive, fraudulent manner,” Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined other contrarians, {like|